CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced the appointment of John D. Mendlein, Ph.D., CEO of aTyr Pharma, to its board of directors.
"I am delighted to welcome Dr. Mendlein to our board," said Katrine Bosley, CEO, Editas Medicine. “His proven track record of building early, dynamic companies and developing new therapeutics for serious diseases will serve as a critical resource for us.”
"I am delighted to welcome Dr. Mendlein to our board," said Katrine Bosley, CEO, Editas Medicine. “His proven track record of building early, dynamic companies and developing new therapeutics for serious diseases will serve as a critical resource for us.”
